Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Strategy May Be Valid Alternative To Traditional Antibiotics
Certainly there is strength in numbers, but only if those numbers can effectively communicate with one another. Now, a new study finds that administration of a novel small molecule which effectively disrupts a key bacterial communication process protects an animal host from infection. The research, published by Cell Press in the July 31st issue of the journal Molecular Cell, may lead to more effective treatments for bacterial infection that won"t encourage growth of treatment resistant bacteria.

AlphaRx And Gaia BioPharma Report Positive Efficacy Results In A Pre-Clinical Trial Of GAI-122 Injectable Nano-emulsion For Post-operative Delirium
AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.
News of the day
Brits Abroad Leave Depressed Friends At Home
New research reveals Brits prefer to rearrange or cancel their summer holiday than go with a friend who has mental illness. The British would prefer to go on their summer holiday with a friend who has a criminal record than go with a friend who has a mental health problem, a new survey as part of the Time to Change campaign [1] has found.
Nutrition

Theratechnologies Presents Results From A Pharmacokinetic/Phamacodynamic Evaluation Of Tesamorelin At The Endocrine Society's Annual Meeting

Theratechnologies (TSX:TH) announced today that results from a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tesamorelin were presented as a poster (Poster number: P3-641) at the Endocrine Society"s 91st Annual Meeting in Washington D.C. Tesamorelin is an analogue of the growth hormone releasing factor evaluated for the treatment of excess abdominal fat in HIV patients with lipodystrophy. The poster outlined the results of two Phase 1 studies performed to determine the PK/PD profiles of tesamorelin after single and multiple administrations of 2 mg of tesamorelin once daily for 14 consecutive days, in healthy volunteers and HIV-positive patients receiving a stable antiretroviral regimen. The results showed that tesamorelin"s PK/PD profiles were generally similar in both groups and suggest that there is a minimal impact on tesamorelin"s PK parameters and on the induction of the insulin-like growth factor (IGF-1) when tesamorelin is given to HIV-positive patients on antiretroviral therapy. Levels of IGF-1 at baseline were within normal range and comparable in both groups (healthy: 175 ng/mL; HIV+: 164 ng/mL). After 14 days of daily injection, a similar increase was observed in healthy volunteers and in HIV-positive patients (115% and 121%, respectively, compared to baseline). In both studies, the extent of absorption (AUC) and the maximal concentration (Cmax) were similar (approximately 700 pgò€¢h/mL and 2400 pg/ml for AUC and Cmax, respectively). The half-life of tesamorelin ranged between 13 to 38 minutes in both healthy volunteers and HIV-positive patients. The poster presented is now available on Theratechnologies" website at http://www.theratech.com About HIV-Associated Lipodystrophy Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence. Theratechnologies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009